Johnson & Johnson ($JNJ) Stock Forecast: Down 5.4% Today

What is Johnson & Johnson?

Johnson & Johnson (JNJ) is a multinational corporation recognized for its healthcare products, pharmaceuticals, and medical devices. It is traded on the NYSE and is a part of the Dow Jones Industrial Average.

Why is Johnson & Johnson going down?

JNJ stock is down 5.4% on Apr 1, 2025 16:55

• The downward trend in JNJ's stock price today is associated with the repeated dismissal of using bankruptcy to resolve talc cancer claims. This legal setback suggests potential financial risks and uncertainties for the company.
• JNJ's choice to contest talc lawsuits instead of settling has reversed $7 billion in legal reserves, indicating a shift in their legal approach that investors may perceive as risky.
• The recent disclosure of positive data from a clinical trial by Nanobiotix is unrelated to JNJ's talc lawsuits and is unlikely to have impacted the bearish movement in JNJ's stock today.
• Concerns about the lasting effects of the ongoing talc litigations on JNJ's finances and reputation may be influencing investors, contributing to the bearish market activity.

JNJ Price Chart

JNJ Technical Analysis

JNJ News

US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims - Johnson & Johnson ( NYSE:JNJ )

A U.S. bankruptcy court rejected J&J subsidiary Red River Talc's prepackaged bankruptcy plan. J&J will litigate talc lawsuits instead of settling, reversing $7 billion in legal reserves and challenging plaintiff claims in court.

https://www.benzinga.com/general/biotech/25/04/44586129/us-judge-rejects-another-johnson-johnson-attempt-to-use-bankruptcy-for-talc-cancer-claims

J&J's Third Bankruptcy Attempt to End Talc Suits Rejected

J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.

https://www.zacks.com/stock/news/2438069/jjs-third-bankruptcy-attempt-to-end-talc-suits-rejected

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

https://www.zacks.com/stock/news/2437556/are-you-looking-for-a-high-growth-dividend-stock

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 ( JNJ-1900 ) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

PARIS and CAMBRIDGE, Mass., March 27, 2025 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext: NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today ...

https://www.globenewswire.com/news-release/2025/03/27/3051020/0/en/Nanobiotix-Announces-First-Data-From-the-Completed-Dose-Escalation-Part-of-a-Phase-1-Study-Evaluating-NBTXR3-JNJ-1900-as-a-2L-Therapy-for-Patients-With-Locally-Advanced-NSCLC.html

Trending Today

NEAR Protocol ($NEAR) Crypto Forecast: Up 5.0% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.1% Today

Memecoin ($MEME) Crypto Forecast: Up 15.5% Today

MANTRA ($OM) Crypto Forecast: Down 6.5% Today

Render ($RENDER) Crypto Forecast: Up 5.2% Today

Kusama ($KSM) Crypto Forecast: Up 5.3% Today

Bonk ($BONK) Crypto Forecast: Up 5.5% Today

Solana ($SOL) Crypto Forecast: Up 5.3% Today

Immutable ($IMX) Crypto Forecast: Up 7.9% Today

Bittensor ($TAO) Crypto Forecast: Up 7.7% Today

Johnson & Johnson Price History

01.03.2025 - JNJ Stock was down 5.3%

• The bearish movement in JNJ stock could be attributed to the announcement from Nanobiotix regarding the first data from a Phase 1 study evaluating NBTXR3 as a therapy for patients with locally advanced NSCLC. This news might have caused some investors to shift their focus towards the potential of this new therapy, leading to a temporary sell-off of JNJ shares.
• The discussion around finding high-growth dividend stocks could have also influenced investor sentiment, with some possibly reallocating their investments based on the perceived growth potential of other dividend stocks.
• Overall, the market movement in JNJ today seems to be driven by a combination of factors related to potential competition in the healthcare sector and the search for high-growth opportunities in dividend stocks.

07.00.2025 - JNJ Stock was up 2.5%

• JNJ stock closed at $144.62 with a +0.89% change from the previous close.
• Smart money is seen to bet big on JNJ options, reflecting a positive outlook on the stock.
• Speculation on JNJ surpassing earnings expectations is contributing to the bullish trend.
• Investors are viewing JNJ favorably amidst market downturns, indicating it as a stable investment in the current economic climate.

07.00.2025 - JNJ Stock was up 2.0%

• The strong bullish movement in JNJ is believed to be influenced by smart money activities in JNJ options, reflecting a positive sentiment from wealthy investors.
• The bearish strategy utilized by these investors might have bolstered confidence in the stock, resulting in a rise in its value.
• The notable surge in JNJ options points towards a general optimism among market participants regarding the company's future prospects, thereby contributing to today's bullish trend in the stock.

15.09.2024 - JNJ Stock was up 2.8%

• Johnson & Johnson reported impressive Q3 earnings with both revenue and EPS beating expectations, driven by strong sales of cancer drugs.
• The revision of annual outlook to reflect the V-Wave acquisition also contributed to the positive sentiment surrounding the stock.
• Analysts revising their forecasts ahead of the earnings call and high-rolling investors positioning themselves bullish on JNJ further added to the optimism in the market.
• The overall positive earnings report and strategic acquisitions seem to have fueled investor confidence, leading to the bullish movement in Johnson & Johnson's stock price today.

26.05.2023 - JNJ Stock was down 1.2%

• JMG Financial Group Ltd. reduced its position in JNJ by 4.2%, which could have contributed to the bearish movement.
• Mayflower Financial Advisors LLC increased its stake in JNJ by 7.1%, which could have offset the bearish movement.
• The news about BlackRock's control over companies, including JNJ, may have caused uncertainty and contributed to the bearish movement.
• The article about the AI tool that beat out top Wall Street analysts may have also caused investors to question the value of traditional analysis methods and contributed to the bearish movement.

06.08.2023 - JNJ Stock was down 2.3%

• The bearish movement of JNJ stock today can be attributed to the following factors:
• 1. Market sentiment: The overall market sentiment might be bearish, leading to a decline in JNJ stock along with other stocks.
• 2. Cidara Therapeutics announcement: The news about Cidara Therapeutics announcing Janssen's election to proceed under its license agreement relating to novel drug-Fc conjugates targeting influenza may have impacted JNJ stock negatively. This announcement could indicate potential competition in the influenza treatment market, affecting investor confidence in JNJ's pharmaceutical division.
• 3. Idorsia deal with Janssen Biotech: The news of Idorsia reaching a deal with Janssen Biotech, affiliated with Johnson & Johnson, for the return of rights for Aprocitentan might have caused some uncertainty among investors. This deal could have implications for JNJ's future drug development pipeline and potentially affect its revenue prospects.
• 4. Arm's IPO ambitions: The news of Arm halving its IPO ambitions to $4.87 billion, surpassing the listing of Johnson & Johnson consumer health spinoff Kenvue, could have indirectly impacted JNJ stock. This news might have shifted investor attention away from JNJ, leading to a decline in its stock price.
• Overall, the bearish movement of JNJ stock today could be influenced by a combination of market sentiment, competition in the influenza treatment market, uncertainty surrounding future drug development, and the diversion of investor attention to other IPOs.

19.06.2023 - JNJ Stock was down 0.3%

• JNJ stock experienced a strong bearish movement today.
• The company was ordered to pay $18.8 million in a talc-related trial, adding to the ongoing litigation surrounding its baby powder.
• JNJ joined other pharmaceutical companies in taking legal action against the U.S. government's drug pricing negotiation program, which could potentially impact the company's profits.
• Despite the bearish movement, Wealth Enhancement Advisory Services LLC showed confidence in JNJ's growth potential by increasing its holdings in the company during the first quarter.
• Overall, the negative legal developments and concerns over potential profit limitations due to the drug pricing negotiation program likely contributed to the bearish movement in JNJ stock today.

20.06.2023 - JNJ Stock was up 4.4%

• The bullish movement in JNJ stock today can be attributed to the following factors:
• 1. Strong Q2 Earnings: Johnson & Johnson reported better-than-expected Q2 earnings, with adjusted earnings per share of $2.80, beating the consensus of $2.62. Sales also increased by 6.3% to $25.5 billion, surpassing the consensus of $24.63 billion. This positive financial performance likely contributed to the bullish market movement.
• 2. Positive Jobs Data: The Australian job market showed better-than-expected results, with an addition of 32.6K jobs, surpassing the expected 15.4K. This positive employment data may have had a spillover effect on JNJ stock, as it indicates a strong economy and potential increased demand for healthcare products.
• 3. Overall Market Sentiment: The broader market sentiment, with the Dow industrial average rising for the 8th consecutive day and the S&P index and Dow industrial average having risen 7 of the last 8 trading days, may have also influenced the bullish movement in JNJ stock.
• 4. DARZALEX Sales: Genmab reported strong worldwide net trade sales of DARZALEX, a product co-developed with Johnson & Johnson. This positive sales report may have indirectly impacted the market sentiment towards JNJ stock.
• Overall, the combination of strong earnings, positive jobs data, favorable market sentiment, and positive sales reports contributed to the bullish movement in JNJ stock today.

17.06.2024 - JNJ Stock was up 4.1%

• JNJ stock showed strong bullish momentum even as the company adjusted its guidance downwards.
• The positive market response could be linked to Johnson & Johnson surpassing earnings expectations, although the stock price dropped due to revised guidance.
• Investor attention may be directed towards JNJ's consistent growth and diverse business model, factors that have historically contributed to the company's ability to navigate different market environments successfully.
• Despite concerns about the revised guidance, JNJ's history of steady earnings growth and sustainable dividend yield may be providing reassurance to investors and fueling the upward trend in the stock.

01.03.2025 - JNJ Stock was down 5.4%

• The downward trend in JNJ's stock price today is associated with the repeated dismissal of using bankruptcy to resolve talc cancer claims. This legal setback suggests potential financial risks and uncertainties for the company.
• JNJ's choice to contest talc lawsuits instead of settling has reversed $7 billion in legal reserves, indicating a shift in their legal approach that investors may perceive as risky.
• The recent disclosure of positive data from a clinical trial by Nanobiotix is unrelated to JNJ's talc lawsuits and is unlikely to have impacted the bearish movement in JNJ's stock today.
• Concerns about the lasting effects of the ongoing talc litigations on JNJ's finances and reputation may be influencing investors, contributing to the bearish market activity.